Sofosbuvir/Daclatasvir Dihydrochloride

索磷布韦/盐酸达拉他韦

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameSofosbuvir/Daclatasvir Dihydrochloride
Drug Alias Name索磷布韦/达拉他韦Sofosdac
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitorsNonstructural protein 5A inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymeraseNonstructural protein 5A
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Hepatitis C, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth AfricaAlgeria
CombinationsYes SofosbuvirDaclatasvir Dihydrochloride
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of The Witwatersrand
China Registration ClassN/A

Develop Information

Active CompaniesPharmaceutical Research UnitUniversity Of The Witwatersrand
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Hepatitis C, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A